To assess if peritumoral administration of BMCs enhances the efficacy of systemically administered GITR agonist and PD-1 blockade, the poorly immunogenic lung cancer cell line, Line-1, was used. This evidence concerns the gene TNFRSF18 and lung carcinoma.